Fuzionaire Radioisotope Technologies K.K. (“FRIT”) today announced that it has entered into a feasibility study agreement with Nihon Medi-Physics Co., Ltd. (“NMP”), a leading radiopharmaceutical company in Japan, engaged in R&D, manufacturing, and distribution.
One of FRIT’s priorities is to apply this fluorine-18 platform to create new radiopharmaceuticals that enable the prediction and measurement of patient responses to cancer immunotherapy treatments. In recent years, there have been extraordinary advances in treatments that help patients’ immune systems fight cancer. However, accurate, optimized patient stratification and selection remains a critical barrier to effective application and development of immunotherapies. Due to the unique capabilities of positron emission tomography – specific, quantitative, real-time, and high-resolution imaging of markers of immunological response – new PET radiopharmaceuticals have the potential to remove that barrier.
To read more please visit:
Source: Business Wire